Characterization of a novel mCH3 conjugated anti-PcrV scFv molecule.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
30 03 2021
Historique:
received: 01 11 2020
accepted: 16 03 2021
entrez: 31 3 2021
pubmed: 1 4 2021
medline: 26 10 2021
Statut: epublish

Résumé

Pseudomonas aeruginosa (PA) is a leading cause of nosocomial infections and death in cystic fibrosis patients. The study was conducted to evaluate the physicochemical structure, biological activity and serum stability of a recombinant anti-PcrV single chain variable antibody fragment genetically attached to the mCH3cc domain. The stereochemical properties of scFv-mCH3 (YFL001) and scFv (YFL002) proteins as well as molecular interactions towards Pseudomonas aeruginosa PcrV were evaluated computationally. The subcloned fragments encoding YFL001 and YFL002 in pET28a were expressed within the E. coli BL21-DE3 strain. After Ni-NTA affinity chromatography, the biological activity of the proteins in inhibition of PA induced hemolysis as well as cellular cytotoxicity was assessed. In silico analysis revealed the satisfactory stereochemical quality of the models as well as common residues in their interface with PcrV. The structural differences of proteins through circular dichroism spectroscopy were confirmed by NMR analysis. Both proteins indicated inhibition of ExoU positive PA strains in hemolysis of red blood cells compared to ExoU negative strains as well as cytotoxicity effect on lung epithelial cells. The ELISA test showed the longer serum stability of the YFL001 molecule than YFL002. The results were encouraging to further evaluation of these two scFv molecules in animal models.

Identifiants

pubmed: 33785781
doi: 10.1038/s41598-021-86491-w
pii: 10.1038/s41598-021-86491-w
pmc: PMC8010009
doi:

Substances chimiques

Anti-Bacterial Agents 0
Antigens, Bacterial 0
Bacterial Toxins 0
Pore Forming Cytotoxic Proteins 0
Recombinant Proteins 0
Single-Chain Antibodies 0
antigen V, Pseudomonas 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

7154

Références

J Mol Biol. 2018 Jul 20;430(15):2237-2243
pubmed: 29258817
J Immunol. 2006 Jan 1;176(1):346-56
pubmed: 16365427
Infect Immun. 2006 Feb;74(2):968-74
pubmed: 16428742
Biotechnol Adv. 2019 Jan - Feb;37(1):177-192
pubmed: 30500353
Biochim Biophys Acta. 2005 Aug 10;1751(2):119-39
pubmed: 16027053
Crit Care Med. 2012 Aug;40(8):2320-6
pubmed: 22622405
Proteins. 2010 Jun;78(8):1950-8
pubmed: 20408171
Protein Eng. 1990 Dec;4(2):155-61
pubmed: 2075190
Curr Protein Pept Sci. 2012 Dec;13(8):831-42
pubmed: 23305368
Traffic. 2007 Oct;8(10):1331-45
pubmed: 17714437
Curr Protoc Bioinformatics. 2016 Jun 20;54:5.6.1-5.6.37
pubmed: 27322406
Biophys Rev. 2016 Dec;8(4):409-427
pubmed: 28510011
Biomolecules. 2021 Jan 04;11(1):
pubmed: 33406810
J Biol Chem. 1989 Oct 5;264(28):16700-12
pubmed: 2506181
J Cyst Fibros. 2018 Jul;17(4):484-491
pubmed: 29292092
Pharmaceutics. 2018 May 18;10(2):
pubmed: 29783687
Antimicrob Agents Chemother. 2014 Aug;58(8):4384-91
pubmed: 24841258
Nat Rev Microbiol. 2009 Sep;7(9):654-65
pubmed: 19680249
J Cyst Fibros. 2020 Jan;19(1):52-67
pubmed: 31526710
J Biol Chem. 2013 Aug 30;288(35):25154-25164
pubmed: 23867459
Nat Med. 1999 Apr;5(4):392-8
pubmed: 10202927
Free Radic Biol Med. 2002 Dec 1;33(11):1527-33
pubmed: 12446210
Science. 1991 Nov 29;254(5036):1374-7
pubmed: 1962196
J Infect Dis. 2002 Jul 1;186(1):64-73
pubmed: 12089663
Nat Biotechnol. 2005 Oct;23(10):1283-8
pubmed: 16186811
Eur J Med Chem. 2019 Jun 15;172:26-35
pubmed: 30939351
Bioinformatics. 2012 Oct 1;28(19):2431-40
pubmed: 22796957
J Mol Biol. 1982 May 5;157(1):105-32
pubmed: 7108955
J Infect Dis. 2018 Nov 5;218(12):1983-1994
pubmed: 30016475
Curr Opin Crit Care. 2018 Oct;24(5):332-338
pubmed: 30036192
Contrast Media Mol Imaging. 2019 Jan 20;2019:2783519
pubmed: 30804723
J Mol Biol. 2016 Feb 22;428(4):720-725
pubmed: 26410586
Microbiol Mol Biol Rev. 1998 Jun;62(2):379-433
pubmed: 9618447
Mol Immunol. 2013 Nov;56(1-2):131-9
pubmed: 23628091
J Immunol. 2010 Feb 15;184(4):1968-76
pubmed: 20083659
Chem Soc Rev. 2016 Sep 21;45(18):4859-72
pubmed: 27347568
Curr Pharm Biotechnol. 2016;17(15):1348-1352
pubmed: 27552847
Sci Transl Med. 2014 Nov 12;6(262):262ra155
pubmed: 25391481
Nucleic Acids Res. 2005 Apr 22;33(7):2302-9
pubmed: 15849316
Infect Immun. 2009 Mar;77(3):1083-90
pubmed: 19103766
Front Biosci. 2003 May 01;8:d661-86
pubmed: 12700066
Bioinformatics. 2016 Dec 1;32(23):3676-3678
pubmed: 27503228
Protein Sci. 1993 Sep;2(9):1511-9
pubmed: 8401235

Auteurs

Samira Komijani (S)

Department of Biotechnology School of Biology, Alzahra University, Tehran, Iran.
Biotechnology Research Center, Pasteur Institute of Iran, No.358, 12 Farvardin St., 1316943551, Tehran, Iran.

Elham Bayat (E)

Department of Molecular and Cellular Sciences, Faculty of Advanced Sciences & Technology, Tehran Medical Branch, Islamic Azad University, Tehran, Iran.
Biotechnology Research Center, Pasteur Institute of Iran, No.358, 12 Farvardin St., 1316943551, Tehran, Iran.

Elham Rismani (E)

Molecular Medicine Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.

Soma Hosseini (S)

Biotechnology Research Center, Pasteur Institute of Iran, No.358, 12 Farvardin St., 1316943551, Tehran, Iran.

Reza Moazzami (R)

Biotechnology Research Center, Pasteur Institute of Iran, No.358, 12 Farvardin St., 1316943551, Tehran, Iran.

Leila Nematollahi (L)

Biotechnology Research Center, Pasteur Institute of Iran, No.358, 12 Farvardin St., 1316943551, Tehran, Iran. Leila.nematollahi@pasteur.ac.ir.

Soroush Sardari (S)

Biotechnology Research Center, Pasteur Institute of Iran, No.358, 12 Farvardin St., 1316943551, Tehran, Iran.

Yeganeh Talebkhan (Y)

Biotechnology Research Center, Pasteur Institute of Iran, No.358, 12 Farvardin St., 1316943551, Tehran, Iran. talebkhan@pasteur.ac.ir.

Fatemeh Davami (F)

Biotechnology Research Center, Pasteur Institute of Iran, No.358, 12 Farvardin St., 1316943551, Tehran, Iran. F_davami@pasteur.ac.ir.

Farzaneh Barkhordari (F)

Biotechnology Research Center, Pasteur Institute of Iran, No.358, 12 Farvardin St., 1316943551, Tehran, Iran.

Fakhrisadat Hosseini (F)

Department of Biotechnology School of Biology, Alzahra University, Tehran, Iran.

Hoda Jahandar (H)

Pharmaceutical Sciences Research Center, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Department of Basic Sciences, Faculty of Pharmacy and Pharmaceutical Sciences, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH